Research Article
Effectiveness and Safety of Panax ginseng Extract on Hepatic Dysfunction: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Table 4
Changes in laboratory tests after 12 weeks of treatment.
| | | GS-KG9 (n = 30) | Placebo (n = 30) | value1) | | Baseline | 12 weeks | Baseline | 12 weeks |
| | WBC (×103/μL) | 6.62 ± 1.87 | 6.58 ± 1.64 | 6.88 ± 1.80 | 6.88 ± 1.86 | 0.924 | | RBC (×1003/μL) | 5.05 ± 0.44 | 4.99 ± 0.39 | 5.26 ± 0.49 | 5.19 ± 0.51 | 0.981 | | Hemoglobin (g/dL) | 15.54 ± 1.32 | 15.39 ± 1.32 | 15.95 ± 1.24 | 15.76 ± 1.20 | 0.707 | | Hematocrit (%) | 46.65 ± 3.90 | 45.85 ± 3.51 | 47.30 ± 3.45 | 46.46 ± 3.44 | 0.993 | | Platelet (×103/μL) | 262.47 ± 75.47 | 258.14 ± 69.09 | 255.17 ± 41.34 | 253.23 ± 44.83 | 0.726 | | Total protein (g/dL) | 7.28 ± 0.59 | 7.10 ± 0.53 | 6.99 ± 1.24 | 7.03 ± 0.39 | 0.329 | | Albumin (g/dL) | 4.48 ± 0.37 | 4.33 ± 0.23 | 4.44 ± 0.38 | 4.30 ± 0.28 | 0.960 | | BUN (mg/dL) | 13.46 ± 3.40 | 13.36 ± 3.26 | 12.80 ± 3.93 | 13.03 ± 3.86 | 0.614 | | Creatinine (mg/dL) | 0.96 ± 0.17 | 0.97 ± 0.13 | 0.94 ± 0.12 | 0.93 ± 0.13 | 0.664 | | Glucose (mg/dL) | 98.93 ± 12.27 | 102.63 ± 14.18 | 106.27 ± 30.94 | 107.03 ± 28.42 | 0.536 | | TC (mg/dL) | 205.47 ± 36.39 | 206.53 ± 34.27 | 216.03 ± 32.12 | 218.40 ± 29.11 | 0.860 | | TG (mg/dL) | 232.57 ± 175.44 | 182.27 ± 129.88 | 257.97 ± 250.73 | 222.37 ± 125.43 | 0.755 | | HDL-C (mg/dL) | 46.23 ± 9.40 | 46.77 ± 8.81 | 45.60 ± 11.70 | 46.23 ± 10.24 | 0.958 | | LDL-C (mg/dL) | 132.77 ± 37.09 | 140.23 ± 35.51 | 141.40 ± 38.21 | 142.00 ± 40.28 | 0.479 | | hs-CRP (mg/L) | 1.47 ± 1.36 | 1.41 ± 1.16 | 1.63 ± 2.50 | 1.30 ± 1.22 | 0.522 |
|
|
Values are presented as mean ± standard deviation. 1)Analyzed by the independent t-test. GS-KG9: Panax ginseng extract; WBC: white blood cells; RBC: red blood cells; BUN: blood urea nitrogen; TC: total cholesterol; TG: triglyceride; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; hs-CRP: highly sensitive-C reactive protein.
|
